Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suppression of Ovarian Function Trial
ISRCTN73368402Phase 3Completed
- Sponsor
- European Institute of Oncology
- Start
- Dec 2003
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, exemestane and triptorelin in breast cancer (3 arms), sponsored by European Institute of Oncology. Started Dec 2003; status: completed.
02
Drugs
tamoxifenexemestanetriptorelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN73368402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73368402.